Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Thursday, Marketbeat reports. They currently have a $2.75 price target on the stock. HC Wainwright’s price target suggests a potential upside of 25.00% from the stock’s previous close.

The analysts wrote, “We note that the next milestone for the company should be the potential approval of YUTIQ three-year treatment of posterior uveitis on or before the PDUFA date of November 5, 2018. As we roll forward our DCF analysis, our estimated market value of the firm has increased to $255M from $245M. Assuming 94.7M shares outstanding at the end of 3Q19, this translates to a per share value to approximately $2.75. Therefore, we reiterate our Buy rating and raise the 12-month price target to $2.75 from $2.50.””

Several other analysts also recently commented on EYPT. ValuEngine downgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Zacks Investment Research downgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Eyepoint Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $4.85.

EYPT stock opened at $2.20 on Thursday. Eyepoint Pharmaceuticals has a 12 month low of $0.93 and a 12 month high of $2.88. The firm has a market capitalization of $123.19 million, a P/E ratio of -3.79 and a beta of 0.97. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 1.57.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, September 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 1,795.71% and a negative return on equity of 323.57%. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $0.67 million. equities research analysts forecast that Eyepoint Pharmaceuticals will post -0.34 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. FineMark National Bank & Trust purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $118,000. California Public Employees Retirement System purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $135,000. Creative Planning purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $162,000. Essex Investment Management Co. LLC purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $170,000. Finally, Bard Associates Inc. purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $189,000. Institutional investors own 62.93% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

See Also: Determine Your Level of Risk Tolerance

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.